Pioglitazone News and Research

RSS
Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

FDA to decide on Avandia’s fate Wednesday

FDA to decide on Avandia’s fate Wednesday

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin mono- and combination therapy improves blood glucose control

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Roche implements risk mitigation plan in taspoglutide Phase III programme

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Vitamin E effective in treating NASH: Study

Vitamin E effective in treating NASH: Study

Daily intake of vitamin E may help improve fatty liver disease: Study

Daily intake of vitamin E may help improve fatty liver disease: Study

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Investigators study Pioglitazone and Vitamin E for treatment of NASH